Opioid-induced constipation in patients with cancer pain in Japan (OIC-J study): a post hoc subgroup analysis of patients with gastrointestinal cancer

被引:5
|
作者
Harada, Toshiyuki [1 ]
Imai, Hisao [2 ,3 ]
Fumita, Soichi [4 ]
Noriyuki, Toshio [5 ]
Gamoh, Makio [6 ]
Okamoto, Masaharu [7 ]
Akashi, Yusaku [4 ]
Kizawa, Yoshiyuki [8 ]
Tokoro, Akihiro [9 ,10 ]
机构
[1] JCHO Hokkaido Hosp, Ctr Resp Dis, Sapporo, Hokkaido, Japan
[2] Gunma Prefectural Canc Ctr, Div Resp Med, Gunma, Japan
[3] Saitama Med Univ, Int Med Ctr, Comprehens Canc Ctr, Dept Resp Med, Hidaka, Saitama, Japan
[4] Kindai Univ, Dept Med Oncol, Nara Hosp, Nara, Japan
[5] Onomichi Gen Hosp, Dept Surg, Onomichi, Hiroshima, Japan
[6] Osaki Citizen Hosp, Dept Med Oncol, Osaki, Miyagi, Japan
[7] Shionogi & Co Ltd, Med Affairs, Osaka, Japan
[8] Kobe Univ, Grad Sch Med, Dept Palliat Med, Kobe, Hyogo, Japan
[9] Natl Hosp Org Kinki Chuo Chest Med Ctr, Dept Psychosomat Internal Med, Sakai, Osaka, Japan
[10] Natl Hosp Org Kinki Chuo Chest Med Ctr, Support & Palliat Care Team, Osaka, Japan
关键词
Cancer pain; GI cancer; Observational study; Opioid-induced constipation; OIC-J; VALIDATION; MANAGEMENT;
D O I
10.1007/s10147-020-01790-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Constipation is a common side effect of opioid therapy. An observational study of opioid-induced constipation (OIC) in Japanese patients with cancer (OIC-J) included 212 patients with various tumor types. This post hoc analysis of OIC-J evaluated a subgroup of patients with gastrointestinal (GI) cancer. Methods Patients were aged >= 20 years, starting strong opioid therapy, had an ECOG PS of <= 2, and must have had >= 3 bowel movements during the week before enrollment. OIC was evaluated for 2 weeks after opioid initiation using the Rome IV diagnostic criteria for colorectal disorders, as well as physician's diagnosis, number of spontaneous bowel movements, Bowel Function Index score, and patient's self-assessment. Relationships between baseline characteristics and OIC incidence, and the effects of OIC on quality of life (QOL) were also explored. Results Fifty patients from OIC-J who had GI cancer [colon (50%), stomach (28%), and esophageal (22%)] were included. OIC incidence varied by which diagnostic criteria were used (46.0-62.0%) and occurred rapidly after initiating opioid therapy. The use of prophylactic laxatives reduced the overall incidence rate of OIC from 71.0% to 47.4%. No baseline characteristics, except comorbidities, were associated with OIC incidence. Change from baseline to day 15 in PAC-SYM total score was significantly greater for patients with OIC versus those without OIC (0.188 versus -0.362;P = 0.0011). Conclusions This post hoc analysis suggests that OIC occurs rapidly in patients with GI cancer after initiating opioid therapy, and negatively impacts QOL. Early and effective intervention strategies may be particularly useful in this group. Additional Information Coauthor Makio Gamoh is deceased.
引用
收藏
页码:104 / 110
页数:7
相关论文
共 50 条
  • [21] Incidence of opioid-induced constipation in non-cancer patients using weak opioids for chronic pain in Japan: a cohort study
    Akira Hashimoto
    Yasuhide Morioka
    Shihomi Wada
    Yuichi Koretaka
    Motoki Sonohata
    Scientific Reports, 15 (1)
  • [22] Overcoming barriers to opioid-induced constipation management in cancer patients
    Martin, Esther Holgado
    Cordellat, Ana Blasco
    Arnau, Marta Guix
    Roldan, Rosa Villatoro
    Yaguee, Almudena Sanz
    Martin, Diana Monge
    Martinez, Fernando Caballero
    Lucas, Francisco J. Campos
    Castano, Almudena Garcia
    SEMINARS IN ONCOLOGY, 2023, 50 (06) : 149 - 154
  • [23] Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
    Chey, William D.
    Webster, Lynn
    Sostek, Mark
    Lappalainen, Jaakko
    Barker, Peter N.
    Tack, Jan
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (25) : 2387 - 2396
  • [24] Impact of opioid-induced constipation on healthcare resource utilization and costs for cancer pain patients receiving continuous opioid therapy
    Perry G. Fine
    Yen-Wen Chen
    Eric Wittbrodt
    Catherine Datto
    Supportive Care in Cancer, 2019, 27 : 687 - 696
  • [25] Impact of opioid-induced constipation on healthcare resource utilization and costs for cancer pain patients receiving continuous opioid therapy
    Fine, Perry G.
    Chen, Yen-Wen
    Wittbrodt, Eric
    Datto, Catherine
    SUPPORTIVE CARE IN CANCER, 2019, 27 (02) : 687 - 696
  • [26] The Efficacy and Safety of Transcutaneous Acupoint Interferential Current Stimulation for Cancer Pain Patients With Opioid-Induced Constipation: A Prospective Randomized Controlled Study
    Zhu, Hua-dong
    Gong, Zhen
    Hu, Bing-wei
    Wei, Qiao-ling
    Kong, Jun
    Peng, Cong-bin
    INTEGRATIVE CANCER THERAPIES, 2018, 17 (02) : 437 - 443
  • [27] Risk factors for opioid-induced constipation in cancer patients: a single-institution, retrospective analysis
    Kanbayashi, Yuko
    Ishizuka, Yuichi
    Shimizu, Mayumi
    Sawa, Shohei
    Yabe, Katsushige
    Uchida, Mayako
    SUPPORTIVE CARE IN CANCER, 2022, 30 (07) : 5831 - 5836
  • [28] A Systematic Review of Naldemedine and Naloxegol for the Treatment of Opioid-Induced Constipation in Cancer Patients
    Braun, Ursula K.
    Jackson, Leanne K.
    Garcia, Mary A.
    Imam, Syed N.
    PHARMACY, 2024, 12 (02)
  • [29] Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis
    Kistemaker, K. R. J.
    Sijani, F.
    Brinkman, D. J.
    de Graeff, A.
    Burchell, G. L.
    Steegers, M. A. H.
    van Zuylen, L.
    CANCER TREATMENT REVIEWS, 2024, 125
  • [30] Opioid-Induced Constipation Survey in Patients with Chronic Noncancer Pain
    Rauck, Richard L.
    Hong, Kyung-soo Jason
    North, James
    PAIN PRACTICE, 2017, 17 (03) : 329 - 335